BioSpace News Archive

IDBS, a leader in enterprise scientific informatics platforms, today announced that Christian Marcazzo has joined the company as Vice President and General Manager, effective immediately.

In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.

Late-stage trial results show that a combination of Bavencio (avelumab) and Inlyta (axitinib) significantly improved progression-free survival in previously untreated patients with advanced renal cell carcinoma.

AAFA Applauds Walgreens and Kaléo Partnership, Increasing Patient Access to Life-Saving Epinephrine

Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.

Although the dominant story in biopharma patent litigation was the federal appeals court backing the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University over the University of California (UC) on CRISPR patents, there have been other patent decisions of note today as well. Let’s take a look.

Shares of Indiana-based Endocyte have slipped more than 3 percent this morning after the company announced the U.S. Food and Drug Administration accepted radiographic progression-free survival as an alternative primary endpoint in its Phase III VISION trial.

Even if you think networking just “isn’t your thing,” you can’t deny the power it holds to help you land the job you want.

Amry today announces that the US Food and Drug Administration (“FDA”) has granted Investigational New Drug (“IND”) clearance for AP101.

Macrophage Pharma Limited announced today the formation of an international Scientific Advisory Board (SAB).